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ABSTRACT 28 
Several procedures based on the shake-flask method and designed to require a 29 
minimum amount of drug for octanol-water partition coefficient determination have 30 
been established and developed. The procedures have been validated by a 28 31 
substance set with a lipophilicity range from -2.0 to 4.5 (log D7.4). 32 
The experimental partition is carried out using aqueous phases buffered with 33 
phosphate (pH 7.4) and n-octanol saturated with buffered water and the analysis is 34 
performed by liquid chromatography. In order to have accurate results, four 35 
procedures and eight different ratios between phase volumes are proposed. Each 36 
procedure has been designed and optimized (for partition ratios) for a specific range of 37 
drug lipophilicity (low, regular and high lipophilicity) and solubility (high and low 38 
aqueous solubility). The procedures have been developed to minimize the 39 
measurement in the octanolic phase. 40 
Experimental log D7.4 values obtained from different procedures and partition ratios 41 
show a standard deviation lower than 0.3 and there is a nice agreement when these 42 
values are compared with the reference literature ones.  43 
SOME CHEMICAL COMPOUNDS STUDIED IN THIS ARTICLE 44 
Atenolol (PubChem CID: 2249); Salicylic acid (PubChem CID: 338); Metoprolol 45 
(PubChem CID: 4171); Caffeine (PubChem CID: 2519); Paracetamol (PubChem CID: 46 
1983); Warfarin (PubChem CID: 54678486); Acetanilide (PubChem CID: 904); 47 
Haloperidol (PubChem CID: 3559); Ketoconazole (PubChem CID: 456201); 48 
Phenothiazine (PubChem CID: 7108) 49 
 50 
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Introduction 56 
Drug discovery is a relevant step in the development of new drugs. The common 57 
procedure is starting with a large number of new potential molecules, test them 58 
against biochemical targets and select the ones that show a significant activity, which 59 
may be considered as candidates for further development. The next stage in 60 
compound selection is identification of those which are more likely to be well 61 
absorbed and distributed in the human body and, although a considerable number of 62 
routes for absorption of drugs through membranes exist, transport by passive diffusion 63 
is the most common one. In order to be absorbed by this route, drugs must be 64 
lipophilic enough to penetrate the lipid cores of membranes, but not so lipophilic that 65 
they get stuck there (Comer, 2003). So lipophilicity, the measure of affinity of a drug 66 
for a lipid environment, has become a parameter of great importance in the 67 
pharmaceutical industry because it indicates the relationship of drugs with their 68 
biological, pharmacokinetical and metabolic properties (Corwin Hansch and Leo, 1979; 69 
Leo et al., 1971; Seydel and Schaper, 1981). 70 
Lipophilicity can be measured by determination of the distribution of a drug between 71 
an organic solvent, generally n-octanol saturated with water, and an aqueous phase. 72 
The partition coefficient (P) refers to the ratio of compound concentration in each 73 
phase and can be determined experimentally by a variety of methods including the 74 
well-known shake-flask method (EPA, 1996; OECD 107 Method, 1995), potentiometric 75 
methods (Avdeef, 1993, 1992; Ràfols et al., 2012; Takács-Novák and Avdeef, 1996), 76 
chromatographic methods (Donovan and Pescatore, 2002; Kaliszan et al., 2002; Liang 77 
and Lian, 2015; OECD 117 Method, 2004; Pallicer et al., 2012, 2010; Wiczling et al., 78 
2008) and others. Besides, lipophilicity can also be estimated using computer software 79 
and extensive studies about the accuracy of calculated log P values by different 80 
computer software has already been carried out (Chou and Jurs, 1979; Leo, 1987; 81 
Mannhold et al., 2009; Pallicer et al., 2014; Tetko et al., 2009). However, when an 82 
ionizable compound is equilibrated in a two-phase system at a pH at which it is 83 
partially ionized, its concentration in the organic and aqueous phases is directly related 84 
to the distribution coefficient (D), which is defined as the ratio of the concentrations of 85 
both the ionized and unionized species of the compound in the organic and aqueous 86 
phases at a determined pH value (Scherrer and Howard, 1977). Both of these 87 
  
coefficients, P and D, are usually expressed through their logarithms as the most 88 
common way to represent lipophilicity. Then, for the general distribution coefficient 89 
 90 
 water
octanol  
c
c
D loglog 
 
 (1) 91 
 92 
where coctanol and cwater represent, respectively, the total drug concentration in the 93 
phase indicated in the subscript. The log D7.4 of a compound stands for its distribution 94 
coefficient at pH 7.4, and it is considered as a property of utmost importance because 95 
of its high physiological relevance and its resemblance to real biological partitions. 96 
Besides, it is accepted by most scientists as one of the most relevant lipophilicity 97 
descriptors to be applied in absorption, distribution, metabolism, excretion and 98 
toxicity (ADMET) studies (Avdeef, 2003; Comer, 2003; Kerns and Di, 2008). The 99 
guidelines about log D7.4 values and their implication for drug development are 100 
illustrated in Table 1 (Comer, 2003; Taylor and Triggle, 2007). 101 
There are many different approaches which can be used to determine a partition 102 
coefficient experimentally (Avdeef, 1993; Donovan and Pescatore, 2002; Gulyaeva et 103 
al., 2008; Hitzel et al., n.d.; Kaliszan et al., 2002; Pallicer et al., 2012, 2010; Ràfols et al., 104 
2012; Stopher and Mcclean, 1990; Takács-Novák and Avdeef, 1996; Valko et al., 2001; 105 
Wiczling et al., 2008), but the most direct one is the shake-flask method. In this 106 
method, an aqueous solution of a compound is mixed in a flask with an organic solvent 107 
(usually water saturated n-octanol). Then, the flask is shaken to equilibrate the sample 108 
between the two phases, and the phases are then separated. Afterwards, the 109 
concentration of analyte is measured in both phases. Because of its simplicity and clear 110 
relationship to the partitioning phenomenon, the shake-flask is the reference method 111 
against other ones when they have to be validated (Comer, 2003).  112 
The well-known shake-flask procedure requires the appropriate selection of the 113 
volumes of solvents to employ and the accurate analysis of the solute in both phases. 114 
It is also necessary to pay attention to a number of other details if high accuracy is 115 
desired, details such as purity of solvents and solutes, solubility of compounds, 116 
quickness of the analytical method, formation of micro-emulsions that prevent phases 117 
from separating, etc. These and other drawbacks regarding the shake-flask method 118 
  
have been previously discussed in the literature (Comer, 2003; Dearden and Bresnen, 119 
1988; Leo et al., 1971; Purcell et al., 1973; Sangster, 1997; Valkó, 2000). 120 
UV spectroscopy and HPLC techniques are most widely used to measure the 121 
concentration of the compound in each phase. HPLC offers some advantages such as it 122 
requires a smaller amount of compound for the measurement and impurities do not 123 
interfere because they are separated from the main component (EPA, 1996; Valkó, 124 
2000). In any case, in order to reduce analysis time, and when no absorption of solute 125 
to vessel glass occurs, only one phase should be analyzed and the concentration in the 126 
other phase is obtained by difference (Leo et al., 1971). From this point of view, a 127 
throughput alternative to classic shake-flask determination has been developed (Valkó, 128 
2000). The method is based on the use of sample chromatographic vials as containers 129 
performing both the equilibration between phases and the analysis of the sample. A 130 
standard solution is used both for the initial compound concentration determination 131 
and for preparation of the partition solutions. To enhance the range of the lipophilicity 132 
that can be achieved, three different octanol/aqueous ratios (0.02; 0.2 and 2) were 133 
proposed. After equilibration, the aqueous phase is injected directly from the crimped 134 
vial to the HPLC system without a separation step. From the analysis of the first vial, 135 
the sample peak is identified and peak areas are calculated for all sample vials. The log 136 
D value is directly calculated by Eq. (2), which derives from Eq. (1) 137 
 138 
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 140 
where Ast and Aw are, respectively, the peak areas of the standard and the aqueous 141 
phase of the partition and Vw and Vo the volumes of water and octanol of the partition. 142 
The method proposed was applied to log D determinations covering a range from -1.5 143 
to 3.5. A limitation of this method is the requirement of a reasonable aqueous 144 
solubility of the compound.  145 
Based on the method above, the purpose of this work is  to establish systematic 146 
experimental procedures able to perform accurate determinations of a wide variety of 147 
compounds covering a log D range between -2 and 4.5. Moreover, this study tries to 148 
get closer to the needs of the pharmaceutical industries and provide them with simple 149 
  
procedures allowing fast routine lipophilicty determination using a very low drug 150 
amount and, eventually, using a DMSO solution of the drug instead of its solid form. 151 
This is because DMSO solutions of drugs are the usual way to keep the bioactive 152 
substances in compound libraries of most pharmaceutical companies. 153 
 154 
2. Fundamentals of the procedures 155 
 156 
Determination of log D values by the traditional shake-flask method requires the 157 
measurement of the compound concentration in octanol and water phases according 158 
to Eq. (1), after equilibration of both phases. Thus, Eq. (1) can be written as: 159 
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 162 
where m stands for the mass of compound, V the volume of the phase and the 163 
subscripts w and o refer to water and organic phase, respectively. 164 
The most precise measurements are obtained when amounts of drug in both phases 165 
are similar. It is evident that this fact depends not only on the particular log D of the 166 
compound, but also on the particular Vw/Vo ratio used in the shake-flask procedure, 167 
because 168 
 169 
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 171 
Fig. 1 presents the fraction of compound that remains in water phase after octanol 172 
equilibration according to its log D value and the particular phase ratio used. For log D 173 
values close to 0, the best results should be obtained when similar volumes of both 174 
phases are equilibrated. However, log D << 0 would require log Vw/Vo << 0 for precise 175 
results, but log D >>0 would require log Vw/Vo >>0. Thus, very hydrophilic or very 176 
hydrophobic compounds may require very low or very high Vw/Vo ratios which can be 177 
difficult and even impossible to handle. The main objective of this work is to set up 178 
appropriate volumes and volume ratio for measuring the log D of drug of different 179 
  
lipophilicity, according to the expected lipophilicity, as well as to develop alternative 180 
methods for a more practical measurement of log D, especially for drugs with extreme 181 
log D values. The tested volumes and ratios, experimentally feasible, are proposed in 182 
Table 2. 183 
The procedure described above requires the HPLC measurement of compound 184 
concentration in octanol and water phases. However, HPLC measurement in octanolic 185 
phases is very cumbersome. Octanol is a high viscosity solvent (Landolt-Börnstein 186 
IV/18B, n.d.) and the injection into a common HPLC column may require a hard and 187 
long time consuming cleaning of the column after used. Moreover, its high viscosity 188 
determines a low volatility (Sangster, 1997) which makes it an inappropriate solvent 189 
for mass spectrometry detection (MS) which is a very common detection technique in 190 
physico-chemical parameter determinations and in analytical drug development 191 
laboratories. 192 
 193 
2.1 Regular lipophilic compounds (Procedure 1) 194 
 195 
For the above reasons, Valkó (Valkó, 2000) proposed the use of the alternative 196 
procedure described in the Section 1 involving the measurement of an aqueous 197 
standard solution which is later equilibrated with octanol. The log D value can be 198 
calculated from HPLC peak areas of the standard and aqueous phase solutions 199 
according to Eq. (1), which can be easily generalized to Eq. (5) if different volumes of 200 
the two measured solutions are injected 201 
 202 
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 204 
where vinj(w) and vinj(st) are the injection volumes of the aqueous phase of the partition 205 
and the standard solution, respectively, and r the adequate dilution factor of the 206 
standard solution. Although the application range of Eq. (5) is the same as that of Eq. 207 
(3), the procedure avoids measuring octanol phases. The most precise results should 208 
  
be obtained for phase ratios close to the D values since when log Vw/Vo = log D, then 209 
mo = mw = mst for Eq. (4). 210 
Of course, the right Vw/Vo ratio cannot be calculated because the log D value is not 211 
known. However, approximate lipophilicity of the test compound can be usually 212 
predicted and an approximate Vw/Vo value derived. Three shake-flask determinations 213 
are proposed: the first partition is done using the Vw/Vo ratio calculated from the 214 
expected log D value, and the second and third ones with a volume ratio much lower 215 
and much higher, respectively. Commonly, at least one of these determinations is 216 
precise enough. In principle, the problem of the procedure may come from drugs of 217 
very low or very high log D values which would require very low or very high Vw/Vo 218 
ratios.   219 
 220 
2.2 Poorly lipophilic compounds (Procedure 2) 221 
 222 
For very low log D values, the lowest feasible Vw/Vo ratios may not be enough to 223 
produce an appreciable partition into the octanolic phase and thus Aw/vinj(w) ~ 224 
Ast·r/vinj(st) and log D cannot be accurately determined from Eq. (5). In this case, the 225 
unique reliable alternative is measuring the octanolic phase, provided that the 226 
detector is sensible enough to measure Ao, and thus calculate log D according to Eq. (6) 227 
which would replace Eq. (5)  228 
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 231 
2.3 Highly lipophilic compounds (Procedures 1b and 3) 232 
 233 
For compounds with very high log D values, Eq. (5) can be used if the detector is 234 
sensitive enough to determine Aw (which will be very small) for the prepared Vw/Vo 235 
ratios. However, in this instance, the problem of highly lipophilic compounds usually 236 
arises from their low aqueous solubility. In this case there are several possibilities. In 237 
some instances, solubility of the standard solution can be increased by adding a 238 
  
cosolvent such as DMSO, currently used to enhance solubility in the drug discovery 239 
process (Procedure 1b). Eq. (5) can be used in this case. If the enhancement of the 240 
solubility by DMSO is not enough, an alternative procedure is to solve the sample in 241 
octanol, instead of water (Procedure 3). To increase the amount of the drug in the 242 
aqueous phase, this stock solution is directly equilibrated with the aqueous phase 243 
without any dilution. Later, the equilibrated aqueous phase and the stock solution, 244 
diluted by an r fator, are measured and log D can be calculated according Eq. (7) 245 
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 248 
These developed procedures (summarized in Fig. 2) shall be tested in this work. 249 
  250 
3. Experimental 251 
 252 
3.1 Instrumentation 253 
 254 
For HPLC measurements, a Shimadzu HPLC system has been employed; the system 255 
consisted of two LC-10ADVP pumps, a SIL-20ACHT auto-injector, a SPD-M10AVP diode 256 
array detector (DAD), a CTO-10ASVP oven and a SCL-10AVP controller. The columns 257 
used have been a XTerra RP-18 (4.6 x 50 mm) column from Waters (Milford, MA, USA) 258 
and a Luna C18 column (4.6 x 50 mm) from Phenomenex (Torrance, CA, USA).  259 
 260 
For UPLC measurements, a Waters Acquity UPLC system with a Waters Acquity diode 261 
array detector has been used. The selected column has been a Waters Acquity UPLC 262 
BEH C18 1.7 m (2.1x50 mm). 263 
 264 
The pH values of water mobile phases have been measured with a Crison 5014 265 
combined electrode, connected to a GLP 22 potentiometer from Crison (Alella, Spain), 266 
with an accuracy of ±0.002 in pH units. The performed partitions have been shaken 267 
  
with a rotation shaker movil-ROD from Selecta (Abrera, Spain) in chromatographic vials 268 
(1,5 mL) or, when the partition volume exceeded the vial capacity, in closed test tubes. 269 
 270 
3.2 Chemicals 271 
 272 
Acetonitrile was 99.9% for HPLC, gradient grade, and has been obtained from Prolabo 273 
(West Chester, PA, USA). Double deionized water has been obtained with a Milli-Q 274 
system from Millipore (Bedford, MA, USA), with a resistivity of 18.2 MΩ•cm. Dimethyl 275 
sulfoxide from Sigma (St. Louis, MO, USA) and n-octanol from Merck (Darmstadt, 276 
Germany) have been also used in this work. A set of 28 compounds from Sigma, 277 
covering log D7.4 values from -2.0 to 4.5, has been chosen in order to carry out this 278 
study.  279 
 280 
3.3 Procedures 281 
 282 
A phosphate pH 7.4 aqueous buffer solution has been prepared and then saturated 283 
with n-octanol. Likewise, an n-octanol solution saturated with pH 7.4 aqueous buffer 284 
has been also prepared. The solubility of octanol in water at room temperature is very 285 
low but the one of water in octanol is fairly high (Sangster, 1997), so the saturation of 286 
both phases before preparing the partitions is mandatory. Both solutions have been 287 
heavily shaken and then left resting for at least 24 hours to ensure complete 288 
separation of the two phases. Once the phases have been prepared, the developed 289 
procedures, which are summarized in Figure 2, have been tested according to the 290 
estimated log D value and solubility of the compound. log D estimation can be 291 
performed by any of the available software packages, ACDlabs (ACD/Labs, 2012) in this 292 
work. Except for Procedure 3, all drugs have been prepared as 10 mM solutions in 293 
DMSO, which is taken as stock drug solution. 294 
 295 
Procedure 1: The drug solution is diluted in the aqueous pH 7.4 phosphate buffer in a 296 
1:100 volume ratio. This solution is taken as standard solution. From it, different 297 
partitions are made with different octanol/water ratios according to approximate log 298 
D7.4 value of the drug. Partitions are shaken for one hour at room temperature. Both 299 
  
the standard solution (conveniently diluted, r, if necessary) and the aqueous phase of 300 
each partition after equilibration are chromatographed for analysis.  301 
 302 
Procedure 1b: This procedure is proposed for hydrophobic compounds which form a 303 
precipitate when the stock solution is diluted with aqueous phosphate buffer. In that 304 
case, the standard solution is prepared by dilution with DMSO (r, usually a dilution 305 
with r = 2 is enough) and chromatographed for analysis. Working partitions are 306 
performed in the same way as Procedure 1. 307 
 308 
Procedure 2:  For hydrophilic compounds, a standard solution is prepared by diluting 309 
the drug solution in the pH 7.4 phosphate buffer in a 1:40 volume ratio. From the 310 
standard solution, the different partitions are made with different octanol/water ratios 311 
according to approximate log D7.4 value of the drug. Partitions are shaken for one hour 312 
at room temperature. After equilibration, both the standard solution (diluted if 313 
necessary) and the octanolic phase of each partition are injected for chromatographic 314 
analysis.  315 
 316 
Procedure 3: For hydrophobic compounds, the drug is dissolved in n-octanol saturated 317 
with aqueous buffer, and then different octanol/water partitions are performed 318 
according to the approximate log D7.4 value of the drug. The standard solution is 319 
prepared by diluting the octanolic solution with water saturated n-octanol (according 320 
to the sensitivity of the chromatographic detector). Partitions are shaken for one hour 321 
at room temperature. Both the octanolic standard and the aqueous phase, after 322 
equilibration of each partition, are chromatographed for analysis.  323 
 324 
Whenever possible three different partitions from Table 2 have been chosen for log 325 
D7.4 determination but in all instances at least two different partitions have been 326 
tested. For each partition two or more replicates have been done. Because agitation 327 
time is a parameter subject to optimization, the log D7.4 values of some selected 328 
compounds have been determined after shaking the partition vials during 1, 2 and 24 329 
hours. No significant differences have been found between the log D7.4 values obtained 330 
at different agitation times. Therefore, shaking the partitions for one hour has been 331 
  
considered enough agitation time to obtain accurate results in the shortest time 332 
possible. 333 
 334 
4. Results and discussion 335 
 336 
4.1 Test of proposed procedures and water/octanol volume ratios 337 
 338 
14 compounds with log D7.4 values covering a range between -2 and 4.5 units have 339 
been selected to test the four procedures described in Section 3.3 (Fig. 2) and the 340 
proposed volume ratios (Table 2). Procedures and volume ratios tested for each 341 
substance have been chosen according to its predicted hydrophobicity and they are 342 
shown in Table 3 as well as the obtained log D7.4 values. These predicted values have 343 
been obtained through the ACDLabs software (ACD/Labs, 2012) and are only used to 344 
give a previous estimation of the lipophilicity which, therefore, allow choosing the 345 
proper partitions. The accepted dispersion of results to assure a precision good enough 346 
when different experimental conditions are involved in the measurement is ± 0.3 347 
logarithmic units (EPA, 1996). Then, and if all the partitions and procedures chosen 348 
work well, all the log D7.4 values obtained for each tested compound should not 349 
present a difference greater than 0.3 logarithmic units. Shaded with grey color are 350 
those that do not fall within the 0.3 logarithmic units range indicating that these 351 
partitions and/or procedures are not suitable for the tested compounds. 352 
It is considered that compounds with intermediate hydrophobicity are those with log D 353 
values between 0 and 2.5. Figure 1 shows that these compounds need volume ratios 354 
between log (Vw/Vo) -1.0 (partition c) and 2.7 (partition h) to have between 10% and 355 
90% of the solute in aqueous and organic phases after equilibration. Then, partitions 356 
from c to h have been tested with compounds which predicted log D7.4 ranges between 357 
-0.13 (caffeine) and 2.73 (butyrophenone). 358 
The results obtained (Table 3) are in concordance with Fig.1 and show that when log 359 
D7.4 value increases, partitions with low volume ratio do not provide results good 360 
enough and partitions with higher volume ratio must be used. Although Fig. 1 shows 361 
that the lowest volume ratio recommended to obtain robust log D values is the one 362 
that implied a 10% of solute mass in aqueous (or octanolic) phase after equilibration, 363 
  
in fact this limit depends on the detector used for quantification. When a 364 
spectrophotometric detector is used, the lowest limit of any partition depends not 365 
only on its sensitivity but also on the absorptivity of the drug. Then, acetanilide, which 366 
has a high absorptivity, can be well detected using partition c although only about 1% 367 
of substance remains in aqueous phase after the equilibration step. However, 368 
haloperidol, which presents low absorptivity, cannot be well detected when about 10% 369 
of the substance remains in aqueous solution after equilibration, that is, when f 370 
partition is involved in the experimental procedure.  371 
Although partition e with Procedure 1 has been used to determine log D7.4 for caffeine 372 
and metoprolol, it is in the lowest log D limit of applicability. On the other end, 373 
partition b with Procedure 2 has also been tested despite it involves a very low 374 
aqueous volume, Vw, difficult to inject properly in the chromatographic system. Thus, 375 
Procedure 2, where the octanolic phase is injected, has been applied and Eq. (6) used 376 
to calculate log D7.4 values. As shown in Table 3, partition b with Procedure 2 does not 377 
work well with caffeine or metoprolol because less than 5-8% remain in aqueous phase 378 
after equilibration (see Fig. 1), this is a 95-92% of the drug partition to octanol phase 379 
and because Ast·r/vinj(st)   ̴ Ao/vinj(o), log D cannot be accurately determined. Nevertheless 380 
the Procedure 2 and partition b in tandem is suitable for log D determinations lower 381 
than -1, such as for atenolol or salicylic acid. Although log D7.4 value obtained with this 382 
partition is lower than the one predicted for salicylic acid, it is consistent to the one 383 
obtained from Procedure 1 and partition c, which are also suitable for this type of 384 
compounds, and very close to the one reported in the literature, -1.65 (Biobyte 385 
Corp.1995-2006, n.d.). In order to obtain robust log D7.4 values for the most hydrophilic 386 
compounds partition c with Procedure 2 has been also performed and no significant 387 
differences have been observed with the log D7.4 obtained with the same partition 388 
applying Procedure 1. 389 
Because of the low solubility of the most hydrophobic compounds (log D > 3.5), 390 
Procedure 1b and Procedure 3 have been also tested using partitions g and h. Table 3 391 
shows the log D7.4 values for phenothiazine and anthracene. For both substances the 392 
log D7.4 values obtained from Procedure 1 are lower than the expected ones whereas 393 
those from Procedure 3 agree with literature (Biobyte Corp.1995-2006, n.d.). It should 394 
be noticed the consistency among values obtained using Procedure 1b (partition h) and 395 
  
Procedure 3 (partitions g or h) despite the first one involves a significant amount of 396 
DMSO in the standard solutions (see Table 3). Thus, the effect of DMSO on measured 397 
log D7.4 seems to be negligible. This assumption is confirmed by results shown in Table 398 
5 for hexanophenone and heptanophenone, compounds not included in Table 3. 399 
According to the results given in Table 3, different procedures and volume ratios are 400 
proposed for compounds covering a wide range of lipophility, as summarized in Table 401 
4. 402 
 403 
4.2 Precision and Accuracy for the developed procedures  404 
 405 
The recommendations proposed in Table 4 have been applied to determine the log D7.4 406 
value of 28 drugs, including the 14 already analysed, within the log D7.4 range between 407 
-1.9 and 4.5. Table 5 shows the results obtained when two different systems (HPLC and 408 
UPLC both with DAD detector) are used to quantify the solute present in aqueous (or 409 
octanolic) phase after equilibration. The obtained results have been compared with 410 
the log D7.4 values recommended in BioLoom database or when there is no 411 
recommended value with the average of the BioLoom values collected at pH 7.4 412 
(Biobyte Corp.1995-2006, n.d.). 413 
At least two different aqueous/octanol volume ratios have been used in all cases and 414 
for each ratio three or more determinations have been done. The mean values and 415 
their standard deviation shown in Table 5 correspond to the ones computed using all 416 
the obtained individual values. When a HPLC-DAD system has been used, the standard 417 
deviation for all the compounds is lower than 0.3 log units, in accordance with the EPA 418 
guidelines for reliable values (EPA, 1996). Eq. (8) shows the correlation between 419 
determined log D7.4 values and the experimental values recommended by the BioLoom 420 
database (Biobyte Corp.1995-2006, n.d.). 421 
 422 
log D7.4(HPLC) = 0.99(±0.01)log D7.4 (BioLoom) -0.01(±0.03) (8) 423 
n = 25 r2 = 0.99  SD = 0.13 F = 4716 424 
 425 
The slope of this correlation is not significantly different from 1 and the intercept from 426 
0 for a 95% confidence level. Thus, it can be assumed that the methodology applied in 427 
  
this work using HPLC-DAD system to quantify the solute provide log D7.4 values 428 
equivalent to those recommended in the literature with a precision of about 0.15 429 
logarithmic units, given as the standard deviation of the correlation. The correlation is 430 
plotted in Fig. 3A. 431 
Fig. 3B and Eq. (9) illustrate equivalence between the log D7.4 values obtained with 432 
UPLC and HPLC systems. 433 
 434 
log D7.4(UPLC) = 0.99(±0.02)log D7.4 (HPLC) + 0.04(±0.04) (9) 435 
n = 25 r2 = 0.99  SD = 0.15 F = 3200 436 
 437 
Again, the slope and the intercept obtained in this correlation are not different from 1 438 
and 0 respectively for a 95% confidence level and thus, no differences in the log D7.4 439 
values are observed when a UPLC system is used instead of HPLC system for 440 
quantifying the solute remaining in aqueous (octanolic) phase, as expected. The 441 
precision is again of 0.15 logarithmic units. However, the injection of octanol in UPLC 442 
cause more overpressures than in HPLC and may produce some troubles in the 443 
chromatographic system. Thus, Procedure 2 and Procedure 3, where the octanolic 444 
phase is injected, are much less suitable when UPLC system is used. In order to 445 
minimize the injection of octanolic phase in this system, partition b with Procedure 1 446 
has been tested for benzoic acid and, although the partition volume of aqueous phase 447 
is small, no difference in log D7.4 value has been obtained with respect to the one from 448 
Procedure 2 with HPLC system showing that Procedure 1 can be extended up to a log D 449 
value of about -1.5. Moreover, Procedures 3 (for HPLC) and 1b (for UPLC and HPLC) 450 
with the proposed partitions work well for very hydrophobic compounds (log D > 3.5). 451 
Therefore, Procedure 1b is a good alternative to Procedure 3 and avoids the injection 452 
of octanol in the chromatographic system. 453 
Finally, the robustness of Procedures 1 and 1b has been checked selecting a new set of 454 
six pharmaceutical compounds in a log D7.4 range between 0.5 and 3.8 and their log 455 
D7.4 value have been determined by three different analysts. The mean values 456 
obtained by these analysts have been compared with the ones obtained by an external 457 
company that provides research services to pharmaceutical laboratories (CEREP). Fig. 4 458 
and Eq. (10) show the correlation obtained between the two set of log D7.4 values: 459 
  
 460 
log D7.4(analyst mean) = 0.98(±0.04)log D7.4 (external company) -0.002(±0.09) (10) 461 
n = 6 r2 = 0.99  SD = 0.09 F = 591 462 
 463 
Because the slope and intercept obtained in this correlation are not significantly 464 
different from 1 and 0 respectively (for a 95% confidence level), it can be concluded 465 
that the proposed procedures for routine “in lab” log D determination can substituted  466 
the external determination procedures common in many pharmaceutical industries. 467 
 468 
5. Conclusions 469 
 470 
The procedures developed in this paper allow fast routine determination of drug 471 
lipophilicity in pharmaceutical laboratory using a small amount of drug. Moreover, 472 
they minimize the HPLC and UPLC measurement in octanolic phases which may be very 473 
hazardous and cleaning time consuming. 474 
Procedure 1 that avoids injection of octanol can be used for log D determination in the 475 
range from -1.5 to 3.5 using the appropriate partition volumes and ratios (Table 4). 476 
This range can be extended up to 4.5 by the use of DMSO as cosolvent if there are 477 
solubility problems (Procedure 1b). 478 
An accurate determination of log D of poorly lipophilic drugs (log D < -1) may require 479 
the injection of the octanolic phase (Procedure 2). Injection of octanolic phase may be 480 
also an alternative for the log D determination of highly lipophilic/low water soluble 481 
drugs (Procedure 3) if the problems associated to octanol injection are considered and 482 
overcome.  483 
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Figure captions 601 
 602 
Figure 1.- Solute fraction remaining in the aqueous phase for different log D values 603 
after equilibration according to aqueous/organic phases volume ratio. a,b,c,d,e,f,g,and 604 
h partitions defined in Table 2Figure 2.- Flow diagrams of the experimental procedures 605 
used in this work. 606 
Figure 3.- Comparison of the log D7.4 values obtained for the set compounds studied. 607 
A) values obtained with the HPLC system vs. values recommended in the BioLoom 608 
reference data and B) log D7.4 values obtained with the UPLC system vs. the ones 609 
obtained with the HPLC system.  610 
Figure 4.- Comparison between experimental log D7.4 values with those from an 611 
external company. Standard deviation error bars are indicated. 612 
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 Table 1. Log D7.4 values and their implications for drug development (adapted from 
reference (Comer, 2003; Taylor and Triggle, 2007)) 
Log D7.4 Implications for drug development 
Below 0 
Intestinal and CNS (central nervous system) permeability problems 
Susceptible to renal clearance 
0 to 1 May show a good balance between permeability and solubility. 
1 to 3 
Probably an optimum range for CNS and non-CNS orally active drugs. 
Low metabolic liabilities. 
Generally good CNS penetration. 
3 to 5 
Solubility tends to become lower. 
Metabolic liabilities tend to increase. 
Above 5 
Low solubility and poor oral bioavailability. 
Erratic absorption. 
High metabolic liability, although potency may still be high. 
 
 
 
Table(s)
 Table 2: Volume ratios and volumes of aqueous (Vw) and 
octanolic (Vo) phases used for proposed partitions. 
Partition Vw (mL) Vo (mL) Vw/Vo log Vw/Vo 
a 0.05 5 0.01 -2 
b 0.2 5 0.04 -1.4 
c 0.5 5 0.1 -1 
d 0.5 0.5 1 0 
e 1 0.1 10 1 
f 1 0.01 100 2 
g 3 0.01 300 2.5 
h 5 0.01 500 2.7 
 
  
Table 3: Study of procedures and volume ratios with tested compounds 
Compound 
Predicted ACDLabsa 
log D7.4 
Procedure Partition Vw/Vo log Vw/Vo 
Measured     
log D7.4
 
Atenolol 
-1.99 
2 a 0.01 -2 -3.01 ± 0.78 
 2 b 0.04 -1.4 -1.76 ± 0.11 
 2 c 0.1 -1 -1.93 ± 0.29 
 1 c 0.1 -1 -1.64 ± 0.07 
 1 d 1 0 -0.58 ± 0.43 
Salicylic acid 
-1.09 
2 a 0.01 -2 -2.31 ± 0.05 
 2 b 0.04 -1.4 -1.77 ± 0.04 
 2 c 0.1 -1 -1.98 ± 0.12 
 1 c 0.1 -1 -1.78 ± 0.10 
 1 d 1 0 -1.35 ± 0.31 
 1 e 10 1 -0.41 ± 0.08 
Metoprolol 
-0.31 
2 b 0.04 -1.4 -0.74 ± 0.03 
 1 c 0.1 -1 -0.20 ± 0.10 
 1 d 1 0 -0.35 ± 0.05 
 1 e 10 1 -0.33 
  1 f 100 2 ---b 
Caffeine 
-0.13 
2 b 0.04 -1.4 -0.40 ± 0.04 
 1 c 0.1 -1 -0.08 ± 0.01 
 1 d 1 0 0.00 ± 0.15 
 1 e 10 1 -0.13 
 1 f 100 2 ---b 
Paracetamol 
0.34 
2 b 0.04 -1.4 1.07 ± 0.01 
 1 c 0.1 -1 0.25 ± 0.01  
 1 d 1 0 0.42 ± 0.03 
 1 e 10 1 0.53 ± 0.20 
 1 f 100 2 1.55 ± 0.17 
Warfarin 
0.62 
1 c 0.1 -1 0.74 ± 0.21 
 1 d 1 0 0.83 ± 0.21 
 1 e 10 1 0.86 ± 0.18 
 1 f 100 2 1.04 ± 0.09 
Acetanilide 
1.08 
1 c 0.1 -1 1.15 ± 0.01 
 1 d 1 0 1.21 ± 0.01 
 1 e 10 1 1.20 ± 0.01 
 1 f 100 2 1.17 ± 0.09 
Acetophenone 
1.66 
1 d 1 0 1.58 ± 0.13 
 1 e 10 1 1.58 ± 0.30 
 1 f 100 2 1.54 ± 0.11 
 1 g 300 2.5 1.61 ± 0.29 
 1 h 500 2.7 1.52 ± 0.21 
Haloperidol 
2.18 
1 d 1 0 1.66 ± 0.05 
 1 e 10 1 2.04 ± 0.26 
 1 f 100 2 2.53 ± 0.06 
 1 g 300 2.5 2.94 ± 0.12 
 1 h 500 2.7 3.08 ± 0.09 
Butyrophenone 
2.73 
1 d 1 0 2.37 ± 0.06 
 1 e 10 1 2.46 ± 0.02 
 1 f 100 2 2.73 ± 0.31 
 1 g 300 2.5 2.68 ± 0.16 
 1 h 500 2.7 2.83 ± 0.16 
Valerophenone 
3.26 
1 d 1 0 2.16 ± 0.14 
 1 e 10 1 2.86 ± 0.02 
 1 f 100 2 3.30 ± 0.15 
 1 g 300 2.5 3.38 ± 0.17 
 1 h 500 2.7 3.47 ± 3.28 
Ketoconazole 
3.43 
1 f 100 2 2.02 ± 0.53 
 1 g 300 2.5 3.50 ± 0.16 
 1 h 500 2.7 3.32 ± 0.21 
Phenothiazine 
4.15 
1 g 300 2.5 3.86 ± 0.43 
 1b g 300 2.5 3.85 ± 0.13 
 3 g 300 2.5 4.21 ± 0.18 
 1 h 500 2.7 3.84 ± 0.15 
 1b h 500 2.7 4.05 ±  0.01 
 3 h 500 2.5 4.01 ± 0.24 
Anthracene 
4.68 
1 g 300 2.5 3.47 ± 0.68 
 1b g 300 2.5 3.99 ± 0.06 
 3 g 300 2.5 4.52 ± 0.21 
 1 h 500 2.7 3.83 ± 0.50 
 1b h 500 2.5 4.24 ± 0.15 
 3 h 500 2.7 4.60 ± 0.11 
a from reference (ACD/Labs, 2012). bcannot be determined  
Shaded values are those that do not fall within 0.3 logarithmic units range. 
.
 

 Table 4: Partitions and shake-flask procedures proposed for log D determination 
log D range Partitions Procedure Equation Observations 
log D < -1 
b, c 
c, d 
2 
1 
6 
5 
 
Partition d only for log D values higher than -1.5 
-1 < log D < 0 c, d 1 5 
 
0 < log D < 1.5 c, d, e 1 5 
Partitions d and e might be used for higher log D 
values if a more sensible detector is used. 
1.5 < log D < 3.0 f, g, h 1 5 
For high log D values the suitability of partition f 
depends on the sensitivity of the detector. 
3.0 < log D < 3.5 g, h 1 5 
 
log D > 3.5 
g,h 
h 
3 
1b 
7 
5 
Procedure 1 could be used if no solubility problems 
are detected 
 
 Table 5: log D7.4 for a set of 28 compounds 
    HPLC – DAD  UPLC – DAD 
Compound 
log D7.4 
BioLoom databasea 
Procedure Partition log D7.4 Average log D7.4 Average 
Atenolol 
-1.94 
2 b -1.76 ± 0.11 
-1.81 ± 0.23 
  
 2 c -1.93 ± 0.29   
 1 c -1.64 ± 0.07   
Salicylic acid 
-1.65 ± 0.59 
2 b -1.77 ± 0.04 
-1.85 ± 0.14 
--- 
-1.43 ± 0.11  2 c -1.98 ± 0.12 --- 
 1 c -1.78 ± 0.10 -1.43 ± 0.11 
Benzoic acid  
-1.43 
2 b -1.37 ± 0.19 
-1.27 ± 0.15 
-1.37 ± 0.01 
-1.27 ± 0.19 
  1 b --- -1.34 ± 0.03 
  1 c -1.22 ± 0.07 -1.32 ± 0.18 
  1 d -1.26 ± 0.20 -1.01 ± 0.07 
Metoprolol -0.15 ± 0.24 
1 c -0.20 ± 0.10 
-0.28 ± 0.10 
-0.38 ± 0.02 
-0.33 ± 0.06 
1 d -0.35 ± 0.05 -0.29 ± 0.05 
Caffeine  
-0.07 
1 c -0.08 ± 0.01 
-0.04 ± 0.12 
-0.04 ± 0.01 
-0.03 ± 0.01   1 d 0.00 ± 0.15 -0.03 ± 0.01 
  1 e --- -0.01 ± 0.02 
Theophylline 
-0.02 
1 c -0.12 ± 0.04 
-0.03 ± 0.09 
-0.02 ± 0.01 
-0.01 ± 0.03  1 d 0.03 ± 0.06 0.02 ± 0.02 
 1 e ---  -0.03 ± 0.03 
Procaine 
0.23 
1 c 0.26 ± 0.15 
0.28 ± 0.17 
0.27 ± 0.06 
0.29 ± 0.05  1 d 0.30 ± 0.21 0.31 ± 0.04 
 1 e --- 0.28 ± 0.01 
Paracetamol 
0.51 
1 c 0.25 ± 0.01 
0.39 ± 0.13 
0.33 ± 0.01 
0.33 ± 0.02  1 d 0.42 ± 0.03 0.34 ± 0.01 
 1 e 0.53 ± 0.20 0.32 ± 0.02 
Warfarin 
0.88 ± 0.28 
1 c 0.74 ± 0.21 
0.83 ± 0.19 
0.96 ± 0.03 
0.91 ± 0.05  1 d 0.83 ± 0.21 0.90 ± 0.04 
 1 e 0.86 ± 0.18 0.88 ± 0.02 
Colchicine 
1.30 
1 c 0.91 ± 0.01 
1.09 ± 0.05 
1.14 ± 0.04 
1.15 ± 0.03  1 d 1.16 ± 0.15 1.14 ± 0.02 
 1 e 1.04 ± 0.01 1.16 ± 0.01 
Acetanilide 
1.16 
1 c 1.15 ± 0.01 
1.19 ± 0.05 
1.18 ± 0.06 
1.19 ± 0.04 
 1 d 1.21 ± 0.01 1.18 ± 0.01 
 1 e 1.20 ± 0.01 1.21 ± 0.02 
 1 f 1.17 ±0.09 --- 
Propranolol 
1.24 ± 0.15 
1 c 1.30 ± 0.04 
1.23 ± 0.05 
1.22 ± 0.02 
1.22 ± 0.06  1 d 1.24 ± 0.02 1.22 ± 0.08 
 1 e 1.19 ± 0.01 1.23 ± 0.08 
Lidocaine 
1.53 ± 0.26 
1 d 1.47 ± 0.33 
1.61 ± 0.26 
1.80 ± 0.07 
1.70 ± 0.19 
 1 e 1.57 ± 0.13 1.78 ± 0.12 
 1 f 1.92 ± 0.01 1.71 ± 0.11 
 1 g --- 1.58 ± 0.31 
 1 h --- 1.73 ± 0.09 
Acetophenone 
1.58 
1 d 1.58 ± 0.13 
1.57 ± 0.16 
--- 
1.55 ± 0.16 
 1 e 1.58 ± 0.30 --- 
 1 f 1.54 ± 0.11 1.52 ± 0.10 
 1 g 1.67 ± 0.29 1.55 ± 0.09 
 1 h 1.52 ± 0.21 1.60 ± 0.12 
Hydrocortisone 
1.61 
1 d 1.54 ± 0.10 
1.58 ± 0.12 
  
 
 1 e 1.54 ± 0.13  
 1 f 1.67 ± 0.06  
Propiophenone 
2.19 
1 d 2.14 ± 0.16 
2.24 ± 0.16 
--- 
1.98 ± 0.19 
 1 e 2.37 ± 0.17 --- 
 1 f 2.17 ± 0.12 2.00 ± 0.16 
 1 g 2.25 ± 0.13 1.88 ± 0.26 
 1 h 2.34 ± 0.09 2.03 ± 0.14 
Butyrophenone 
2.66 
1 d 2.37 ± 0.06 
2.65 ± 0.23 
--- 
2.66 ± 0.10 
 1 e 2.46 ± 0.02 --- 
 1 f 2.73 ± 0.31 2.64 ± 0.07 
 1 g 2.68 ± 0.16 2.59 ± 0.09 
 1 h 2.83 ± 0.16 2.73 ± 0.10 
Haloperidol 
2.92 ± 0.34 
1 f 2.53 ± 0.06 
2.77 ± 0.26 
2.78 ± 0.08 
2.78 ± 0.09  1 g 2.94 ± 0.12 2.79 ± 0.10 
 1 h 3.08 ± 0.09 2.79 ± 0.09 
Valerophenone 
--- 
1 f 3.30 ± 0.15 
3.40 ± 0.14 
--- 
3.22 ± 0.12  1 g 3.38 ± 0.17 3.13 ± 0.08 
 1 h 3.47 ± 0.07 3.31 ± 0.04 
Napththalene 
3.3 
1 g 3.05 ± 0.08 
3.19 ± 0.14 
2.89 ± 0.01 
3.21 ± 0.25 
 1 h 3.28 ± 0.02 3.37 ± 0.10 
Thymol 
3.3 
1 g 3.43 ± 0.27 
3.34 ± 0.23 
3.34 ± 0.06 
3.32 ± 0.05 
 1 h 3.29 ± 0.19 3.31 ± 0.04 
Ketoconazole 
3.83 
1 g 3.50 ± 0.16 
3.42 ± 0.20 
3.39 ± 0.18 
3.36 ± 0.15 
 1 h 3.32 ± 0.21 3.28 ± 0.01 
Reserpine 
3.72 
3 f 3.67 ± 0.08 
3.89 ± 0.21 
--- 
4.27 ± 0.18  3 g 4.02 ± 0.11 4.44 ± 0.05 
 3 h 3.98 ± 0.21 4.11 ± 0.03 
Hexanophenone 
--- 
3 g 3.72 ± 0.26 
3.69 ± 0.23 
3.86 ± 0.02 
4.05 ± 0.32 
 3 h 3.67 ± 0.21 4.54 ± 0.03 
 1b g  3.71 ± 0.01 
 1b h  4.07 ± 0.02 
Phenothiazine 
4.15 
3 g 4.21 ± 0.18 
4.11 ± 0.22 
3.87 ± 0.02 
4.02 ± 0.04  3 h 4.01 ± 0.24 4.02 ± 0.02 
 1b h   4.05 ± 0.01 
Heptanophenone 
--- 
3 g 4.42 ± 0.21 
4.41 ± 0.27 
4.33 ± 0.02 
4.52 ± 0.16  3 h 4.41 ± 0.38 4.65 ± 0.04 
 1b h   4.59 ± 0.13 
Anthracene 
4.45 
3 g 4.52 ± 0.21 
4.49 ± 0.23 
4.65 ± 0.02 
4.37 ± 0.23  3 h 4.47 ± 0.24 --- 
 1b h   4.24 ± 0.15 
Phenanthrene 
4.47 
3 g 4.62 ± 0.11 4.58 ± 0.09   
 3 h 4.55 ± 0.07    
afrom reference (Biobyte Corp.1995-2006, n.d.). Values without standard deviation correspond 
to the recommended ones, whereas the ones with standard deviation correspond an average 
of the collected values.  
